Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study - Wikidata - wikimedia - TriplyDB

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

http://www.wikidata.org/entity/Q35230210

about

Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.Identification and validation of vertebral compression fractures using administrative claims data.Longitudinal change in clinical fracture incidence after initiation of bisphosphonates Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.Risedronate's efficacy: from randomized clinical trials to real clinical practice.Efficacy of ibandronate: a long term confirmation.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.Osteoporosis therapies: evidence from health-care databases and observational population studies.Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates.Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review.Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis Contralateral hip fractures and other osteoporosis-related fractures in hip fracture patients: incidence and risk factors. An observational cohort study of 1,229 patients.Clinical role of bisphosphonate therapy.An opportunity for improving osteoporosis treatment in home health care OSTEOPOROSIS DIAGNOSIS AND TREATMENT.Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.Proximal humeral fracture as a risk factor for subsequent hip fractures RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.Effectiveness of antiresorptives for the prevention of nonvertebral low-trauma fractures in a population-based cohort of women New dosing options in osteoporosis treatment: clinical evidence on Risedronate 75mg monthly treatment.Role of observational studies in assessing osteoporosis therapies: the REAL study.The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.Coordinator-based systems for secondary prevention in fragility fracture patients.Individualizing osteoporosis therapy.Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments.Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.Evaluation of the effect of 4 months of risedronate therapy on femoral strength using femoral strength analysis tools.Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits.

P2860

Q26864549-9E7322E7-8293-4FA7-8EB7-701E092B54AC Q33305959-7234757A-472A-4415-94F7-E5E616EBD596 Q33395609-754DF3D3-314E-4580-BFA9-D116806A3C5F Q33819111-BE005FB9-D224-49BE-AFEB-D1643BE9E939 Q33841863-06112FCA-2DD9-4C5E-8EB6-1A9C2366124B Q33958113-A81119D4-98C5-40D5-95F7-A7D3000ACC08 Q33965652-DEDF2441-913A-495A-B094-B3A298AC1CC0 Q33965657-5EB7170D-C0BD-4E45-A7A9-94FE85A624A2 Q34009569-66580B69-F3F4-4764-8563-BE2CC6018461 Q34018048-7CACC07D-6B67-4FBF-9F62-8EE83834D7C2 Q34242906-8EBBE0A9-B670-4099-82BB-5E08B43CE199 Q34522484-37DBF5B0-FEEA-4AFD-98E5-32F0D9029049 Q34658660-7D59059A-8895-47AC-9743-1F54EA1EAB3C Q35678676-B6C4E0B9-0517-430A-87D8-B74F18D72D5A Q35774970-8A856540-E965-47D2-B1FA-D39CDFFD105B Q36056975-F7A003D1-7D55-4772-A1FE-FFE004883B08 Q36059535-02598CF8-3F5A-43FE-B578-BAB581F5F2E4 Q36105275-34E5A98F-4207-4A5E-AFBF-537DE3663F8C Q36311593-620385DB-6B12-4AB7-95BC-697864C504EB Q36683964-5FBA7A6D-3655-4979-9516-FF3CA90455A4 Q36703994-6183F0CF-F9D7-4AD2-AF2A-AA2CBFD421A2 Q36897441-A315C9F8-DE52-45E2-BD82-224C7DABF3BE Q36952170-C1CB6DF7-F532-4CB2-A45D-89D0235D4488 Q37160081-3B4D40EB-C063-42F5-87E4-FADF8E1AE96C Q37264078-721A3F7B-B4FE-4FD2-B077-CD9AAE4DB7AC Q37392009-D2276BED-F8C8-4C5E-B485-86EE97518BC0 Q37401847-200AFFA6-8187-4760-A56D-CCDAF7F59AC3 Q37430360-8644C4F7-82FB-452A-9471-9B2D36B44D57 Q37430500-3DD77C90-F405-4451-8A3F-F23E23E26EA6 Q37832692-DCF35324-9DB3-4979-A02E-11B977EE3EEF Q37862933-C36ECA6B-FACB-4CC5-93F3-737E2C256D63 Q37879009-4AC81C93-875F-4652-83F1-455034EF17D6 Q37973239-62DBE975-96A7-4AF5-9E21-0CF71AA5FD0B Q38014250-F961BC9D-B6F1-4F0D-B826-398AD7AA0E74 Q42108489-98D6E644-DBA0-465D-9DA5-568CA959044F Q43166167-B30A971E-D7DD-4626-9760-EEDB59789951 Q43166707-1D59243B-A781-4BFD-ADE8-06DF68B597B4 Q44381104-B875924F-9EAB-4239-895C-FB5FD396112E Q44574043-E34C0290-2A64-4ED5-AB25-CC7C2D9D3317 Q45997666-5A4D4195-3644-41B2-B770-420E226B19DB

P2860

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

http://www.wikidata.org/entity/Q35230210

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study

@ast

Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study

@en

type

label

Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study

@ast

Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study

@en

prefLabel

Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study

@ast

Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study

@en

P1433

Q35230210-04B66FBC-4C8B-4DAE-9087-F2BC875B96AE

P1476

Q35230210-866469C0-DEDB-4C54-9068-9BCFA524AD23

P2093

Q35230210-145F52B9-0B8B-4FAD-9E10-B375515C7A46

Q35230210-78EC0640-C47F-4ADD-B774-09EEE5455DAE

Q35230210-93E1F191-35C4-4AD6-A5B6-7EE81C326627

Q35230210-A77FE7EC-2EBA-4933-B007-26F9580DE8E6

Q35230210-B8F4B6CE-056D-42E5-8D27-A665E7C03121

P2860

Q35230210-138114EA-C921-4E33-9FE5-F9B57BC24538

Q35230210-1FBEA7F5-E62A-42CC-A02F-F594C75CE278

Q35230210-26B07CF4-6CFF-498E-94D3-1343B833F495

Q35230210-310D0D57-9FFF-4CC9-A291-D1BDECD81CE9

Q35230210-337400CD-C92B-470F-8C14-08B5F080C38F

Q35230210-34945B86-32C5-48EE-9FA7-F98608F33171

Q35230210-4771469C-D36E-4419-BD24-F1858AEFA4A4

Q35230210-49A975B5-285F-49D2-8D83-ADC58E188397

Q35230210-555385E6-F22D-44EF-9D35-2A6EB2153D88

Q35230210-58D1AC2A-B44E-4EC8-B4CA-183DCD216579

P2888

Q35230210-14A5ACE2-FA5E-427A-B384-B3422F947491

P304

Q35230210-4CDA8F3D-73A7-4D1E-9163-25054F951AE2

P31

Q35230210-0D506086-09FB-43DB-9375-BF81F5A234AE

P356

Q35230210-74ED5051-051C-4724-9D43-7830AC613E4E

P407

Q35230210-53A558DD-1B0F-4570-AFA3-1A585CC67EE5

P433

Q35230210-6BDAE35A-E360-4A9E-947D-50F4D5DC4EF0

P478

Q35230210-CC0A7100-AC01-4A35-9D27-67245161E8DF

P577

Q35230210-E3823434-0D32-48AE-9057-72C99D8C2089

P5875

Q35230210-86F60650-4638-42C9-B499-D30C2377FA8C

P698

Q35230210-F779BB5E-5FF2-4876-BACD-D3FF4E138151

P932

Q35230210-CB231EDB-0F10-4AAE-ABF1-74A8ED1DFF3C

P356

S00198-006-0274-Z

P1433

Osteoporosis International

P1476

Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study

@en

P2093

J L Lange

http://www.w3.org/2001/XMLSchema#string

N B Watts

http://www.w3.org/2001/XMLSchema#string

P D Delmas

http://www.w3.org/2001/XMLSchema#string

R Lindsay

http://www.w3.org/2001/XMLSchema#string

S L Silverman

http://www.w3.org/2001/XMLSchema#string

P2860

Why we need observational studies to evaluate the effectiveness of health care

Estimating medication persistency using administrative claims data.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.

Study subjects and ordinary patients.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.

Methods to assess intended effects of drug treatment in observational studies are reviewed.

P2888

s00198-006-0274-z

P304

25-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-006-0274-Z

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6690574

http://www.w3.org/2001/XMLSchema#string

P698

17106785

http://www.w3.org/2001/XMLSchema#string

P932

1705543

http://www.w3.org/2001/XMLSchema#string